Statistics

Total Visits

Views
FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-alpha blockers in psoriatic arthritis: A longitudinal study with 6 months of followup50

Select a period of time:

Number of views in the range

Views
FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-alpha blockers in psoriatic arthritis: A longitudinal study with 6 months of followup27

Views

Views
October 20242
November 20241
December 20241
January 20254
February 20256
March 202513
April 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore14
United States10
Spain2
United Kingdom1
 

Top cities views

Views